Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J S Penta

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
American Journal of Clinical Oncology|February 1, 1982
PCNU: a new nitrosourea in clinical oncologyD S Poster, J S Penta, S Bruno
Cancer Chemotherapy and Pharmacology|January 1, 1992
Choice of starting dose and escalation for phase I studies of antitumor agentsJ S Penta, G L Rosner, D L Trump
Cancer Treatment Reviews|June 1, 1981
The nitrosoureas and pulmonary toxicityR B Weiss, D S Poster, J S Penta
Annals of Internal Medicine|August 1, 1977
Hepatotoxicity of combination chemotherapy for acute myelocytic leukemiaJ S Penta, D D Von Hoff, F M Muggia
JAMA|May 22, 1981
delta 9-tetrahydrocannabinol in clinical oncologyD S Poster, J S Penta, S Bruno, et al.
Journal of Clinical Pharmacology|August 1, 1981
Clinical trials with antiemetic agents in cancer patients receiving chemotherapyJ S Penta, D S Poster, S Bruno, et al.
Cancer Clinical Trials|January 1, 1981
ICRF-187 in clinical oncologyD S Poster, J S Penta, S Bruno, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1979
Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for phase I clinical trialsJ S Penta, M Rozencweig, A M Guarino, et al.
Cancer Clinical Trials|January 1, 1981
2'-deoxycoformycin. A new anticancer agentD S Poster, J S Penta, S Bruno, et al.
Cancer Treatment Reports|July 1, 1977
Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administrationD D Von Hoff, J S Penta, L J Helman, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
American Journal of Clinical Oncology|February 1, 1982
PCNU: a new nitrosourea in clinical oncologyD S Poster, J S Penta, S Bruno
Cancer Chemotherapy and Pharmacology|January 1, 1992
Choice of starting dose and escalation for phase I studies of antitumor agentsJ S Penta, G L Rosner, D L Trump
Cancer Treatment Reviews|June 1, 1981
The nitrosoureas and pulmonary toxicityR B Weiss, D S Poster, J S Penta
Annals of Internal Medicine|August 1, 1977
Hepatotoxicity of combination chemotherapy for acute myelocytic leukemiaJ S Penta, D D Von Hoff, F M Muggia
JAMA|May 22, 1981
delta 9-tetrahydrocannabinol in clinical oncologyD S Poster, J S Penta, S Bruno, et al.
Journal of Clinical Pharmacology|August 1, 1981
Clinical trials with antiemetic agents in cancer patients receiving chemotherapyJ S Penta, D S Poster, S Bruno, et al.
Cancer Clinical Trials|January 1, 1981
ICRF-187 in clinical oncologyD S Poster, J S Penta, S Bruno, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1979
Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for phase I clinical trialsJ S Penta, M Rozencweig, A M Guarino, et al.
Cancer Clinical Trials|January 1, 1981
2'-deoxycoformycin. A new anticancer agentD S Poster, J S Penta, S Bruno, et al.
Cancer Treatment Reports|July 1, 1977
Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administrationD D Von Hoff, J S Penta, L J Helman, et al.
Pageof 2